Document:

Exhibit 10.4

                              EMPLOYMENT AGREEMENT

      Agreement made as of July 1, 2004, between MEDASORB TECHNOLOGIES, LLC, a
Delaware Limited Liability Company with offices at 7 Deer Park Drive, Suite K,
Monmouth Junction, NJ 08852 ("MEDASORB") and DR. JAMES WINCHESTER, an individual
residing at 1323 Pine Tree Road, McLean, Virginia 22101-2416 ("WINCHESTER")

                                    RECITALS

      WHEREAS, MEDASORB is engaged in the development and sale of certain
medical technology including the development and production of a polymer resin
useful in the treatment of blood purification, and

      WHEREAS, MEDASORB desires to employ WINCHESTER, and WINCHESTER desires to
serve MEDASORB as its Chief Medical Officer ("CMO") with administrative and
technical responsibilities.

                               TERMS OF AGREEMENT

In consideration of the foregoing and the mutual promises set forth below, the
parties agree as follows:

1.    TERM:

      1.1   The term of this Agreement shall be one (1) year commencing July 1,
            2004 ("Effective Date") and expiring on June 30, 2005 (the "Term").
            The Term of this Agreement shall be automatically renewed for
            successive one year periods thereafter unless within 90 days prior
            to the end of the initial term or the end of any renewal year,
            either party gives the other written notice of its intention not to
            renew in which event this Agreement shall terminate at the end of
            the initial Term or the end of that renewal year term.

2.    EMPLOYMENT DUTIES:

      2.1   So long as this Agreement continues in effect, WINCHESTER will
            devote his full business time and energies to the business and
            affairs of MEDASORB as CMO and shall not engage in any other-part or
            full-time outside employment or business activity (other than
            passive investment) unless specifically agreed to in writing by
            MEDASORB or as otherwise set forth on Exhibit A. WINCHESTER will use
            his best efforts, skill and abilities to promote MEDASORB's
            interests and perform the customary duties of a CMO including,
            without limitation: overseeing all clinical trials conducted by
            MEDASORB, which shall include interfacing with MEDASORB's product
            development department and patients, clinicians and technicians;
            organizing, implementing and managing pre-clinical studies and other
            clinical research; assisting in the management of MEDASORB by
            participating in decisions relating to product manufacture and/or
            sourcing, product development and qualification, vendor selection,
            development of technical specifications, and long-term research and
            development; and any other duties which may be reasonably assigned
            to him by the Board of Managers.

<PAGE>

3.    REMUNERATION:

      3.1   Salary: MEDASORB will pay WINCHESTER, for his services hereunder a
            base salary ("Base Salary") of One Hundred Twenty Thousand Dollars
            ($120,000) per annum, payable in accordance with the usual payroll
            practices of MEDASORB, but not less frequently than bimonthly
            installments.

      3.2   Performance Bonus Plan: WINCHESTER shall at the discretion of the
            Managers, be entitled to participate in any bonus plan provided to
            senior executives including stock option plans, profit sharing plans
            and/ or their equivalent.

4.    BENEFITS:

      4.1   Insurance

            MEDASORB will not be responsible for WINCHESTER's life, medical, or
            disability insurance. MEDASORB will continue WINCHESTER's insurance
            coverage currently in place for a period of up to 120 days from the
            date of this Agreement until such time as WINCHESTER notifies
            MEDASORB that he has established his own private insurance plan.

      4.2   Travel Expenses

            During the Term of this Agreement MEDASORB will reimburse
            WINCHESTER for approved business travel expenses incurred.

5.    VACATION TIME:

      WINCHESTER will be entitled to vacation time in accordance with the
      customary practices of MEDASORB regarding senior executives which time,
      however, shall not be less than three weeks per year. WINCHESTER shall
      take vacation hereunder during each year of this Agreement at reasonable
      times considering the business activities of MEDASORB.

6.    EXPENSES:

      MEDASORB will pay or reimburse WINCHESTER for all reasonable and necessary
      expenses incurred or paid by Employee in connection with the performance
      of his services under this Agreement, on presentation pf expense
      statements or vouchers and such other supporting information as is
      customarily required by MEDASORB.

7.    DISABILITY:

<PAGE>

      7.1   If during the Term, WINCHESTER, by reason of physical or mental
            disability or incapacity, shall be unable to perform his duties
            hereunder for ninety (90) successive days or a period of one hundred
            twenty (120) days in the aggregate in any year of the Term,
            MEDASORB, at its option, may terminate this Agreement by written
            notice to WINCHESTER given within fifteen (15) days after the end of
            such ninety (90) or one hundred twenty (120) day period.

      7.2   If this Agreement is terminated under Section 7.1, MEDASORB shall
            pay WINCHESTER his salary through the date of termination.

8.    DEATH

      If WINCHESTER should die during the Term, MEDASORB shall pay to such payee
      or payees as he has designated by written notice to MEDASORB, or in
      default of such designation then to his estate, all Base Salary and
      Benefits through the date of death.

9.    TERMINATION OF EMPLOYMENT:

      9.1   Notwithstanding any other provision of this Agreement, WINCHESTER's
            employment may be terminated prior to the end of the Term hereof as
            follows:

            9.1.1 Automatically upon the death of WINCHESTER, in which event the
                  provisions of Article 8 hereof shall govern;

            9.1.2 Upon a finding of disability of WINCHESTER pursuant to Article
                  7, in which event the provisions of that Article shall govern;

            9.1.3 At MEDASORB's option, on dismissal of WINCHESTER for "Cause".
                  "Cause" shall mean one or more of the following:

                  (a)   The willful commission by WINCHESTER of a dishonest , or
                        tortuous act, as such is reasonably and in good faith
                        determined by the Managers, with respect to MEDAORB or
                        any subsidiary or affiliate thereof; or

                  (b)   WINCHESTER is convicted of a criminal act (MEDASORB may
                        suspend WINCHESTER without pay upon indictment for
                        commission of a crime); or

                  (c)   WINCHESTER's failure to perform a substantial portion of
                        his duties and responsibilities hereunder, which failure
                        continues for more than ten (10) days after receipt by
                        WINCHESTER of written notice given by the Managers of
                        MEDASORB, setting forth in reasonable detail the nature
                        of such failure; or

<PAGE>

                  (d)   Alcoholism or drug abuse; or

                  (e)   Breach by WINCHESTER of any material provisions of this
                        Agreement or the rules or policies established by the
                        Managers; or

                  (f)   Willful misconduct or negligence by WINCHESTER in the
                        performance of his duties under this Agreement.

            9.1.4 On dissolution of MEDASORB or on cessation by MEDASORB of
                  active operations, provided in either case, not in connection
                  with the conversion of MEDASORB from a Limited Liability
                  Company to a "C" corporation.

10.   NON-DISCLOSURE OF CONFIDENTIAL INFORMATION; INVENTIONS; SHOP RIGHTS:

      10.1  WINCHESTER shall not use or disclose to any person or entity any
            confidential information relating to MEDASORB including, but not
            limited to, technical, scientific or medical information, or
            information relating to its business operations including, but not
            limited to, its customer list, financial information, sales and
            marketing data, or its manufacturing methods and/or arrangements,
            obtained during the course of his employment, without MEDASORB's
            prior written consent.

      10.2  Every invention, discovery or improvement made or conceived by
            WINCHESTER during his employment by MEDASORB, whenever or wherever
            made or conceived, and whether or not during business hours, of any
            product, tool, device, formula, or process, software program similar
            to, or which constitutes an improvement, on those heretofore, now or
            at any time during his employment, developed or used by MEDASORB in
            connection with the development, design, or process of any product
            related to MEDASORB's business, or of any product which shall or
            could reasonably be developed, designed, or marketed in the
            reasonable expansion of the business of MEDASORB, shall be and
            continue to remain MEDASORB's exclusive property without any added
            compensation or any reimbursement for expenses to WINCHESTER, and
            upon the conception of any and every such invention, discovery or
            improvement and without waiting to perfect or complete it,
            WINCHESTER promises and agrees that he will immediately disclose it
            to MEDASORB and to no one else and thenceforth will treat it as the
            property and secret of MEDASORB. WINCHESTER will also execute any
            instruments reasonably requested from time to time by MEDASORB to
            vest in MEDASORB complete title and ownership to such invention,
            discovery or improvement and will, at the request of MEDASORB, do
            such acts and execute such instruments as MEDASORB may require but
            at MEDASORB's expense to obtain Letters Patent in the United States
            and foreign countries, for such invention, discovery or improvement
            and for the purpose of vesting title thereto in MEDASORB, without
            any additional compensation of any kind to WINCHESTER.

<PAGE>

11.   COVENANTS NOT TO COMPETE AND OTHER PROVISIONS

      11.1  "Competitive Activity" as used herein shall mean (i) engaging
            directly or indirectly, on behalf of himself or in any way on behalf
            of any other person, corporation or other entity, in any advising,
            investing, consulting or other business activity including becoming
            employed by, or acting as an agent or principal or any person, firm,
            corporation or other entity that is engaged in any business activity
            relating in any manner to any product, process, service or business
            activity that competes or potentially could compete with any
            product, process, service or business activity of MEDASORB or any
            product, service or activity being developed by MEDASORB or whose
            development, to the extent WINCHESTER knows or has reason to know,
            is being contemplated by MEDASORB, including but not limited to
            products or services relating to the detoxification of blood with
            adsorbent polymers or the use of adsorbent polymers in any other
            medical application; (ii) accepting employment with or being
            directly or indirectly involved as an independent contractor,
            consultant or otherwise with any company that is, or has been at any
            time in the prior twelve months, a customer or client of MEDASORB;
            (iii) soliciting for employment or consulting, employing or
            retaining, or assisting another person to employ or retain, directly
            or indirectly, any employees of MEDASORB or any person who was an
            employee of MEDASORB in the prior twelve months; provided, however,
            that employing or retaining, or assisting another person to employ
            or retain, any person whose employment with MEDASORB has been
            terminated without Cause shall not be considered Competitive
            Activity; (iv) soliciting, contacting, or otherwise doing business
            with any person that is, or at any time in the prior twelve months
            has been, a customer, licensor, licensee, client, agent, broker or
            dealer of or for MEDASORB.

      11.2  In consideration of this Agreement WINCHESTER agrees during the Term
            and for a period ending one year following the date of termination
            of this Agreement, not to engage in any Competitive Activity, except
            as consented to by MEDASORB in writing. Notwithstanding the
            foregoing, in no event will WINCHESTER be prohibited from engaging
            in the practice of medicine as a nephrologist.

      11.3  WINCHESTER acknowledges that MEDASORB will suffer irreparable harm
            in the event WINCHESTER reveals any confidential information
            relating to MEDASORB, or during any restricted period engages or
            threatens to engage in any Competitive Activity or any activity in
            violation of this Agreement, and therefore, agrees that in addition
            to its remedies by law, MEDASORB shall be entitled to injunctive
            relief as a consequence of a violation or threatened violation of
            the provisions of this Agreement.

<PAGE>

      11.4  On the expiration or earlier termination of the Term or WINCHESTER's
            resignation, discharge or earlier departure from MEDASORB,
            WINCHESTER shall promptly surrender to MEDASORB all of MEDASORB's
            books, records, documents, and customer lists and/or other of
            MEDASORB's materials or records he may have in his possession.

12.   NOTICES:

      All notices, requests, demands and other communications hereunder shall be
      in writing and shall be deemed to have been duly given if hand delivered
      or mailed, by certified mail, return receipt requested, as follows:

      To Company:

            MedaSorb Technologies, LLC
            7 Deer Park Drive, Suite K
            Monmouth Junction, NJ  08852

      To Attorney:

            Rubin Bailin Ortoli Mayer Baker & Fry LLP
            405 Park Avenue, 15th Floor
            New York, NY 10022
            Attn. Joseph Rubin, Esq.

      To Employee:

            Dr. James Winchester
            1323 Pine Tree Road
            McLean, VA 22101-2416

      With a copy to:

      and/or to such persons and addresses as any party shall have specified in
      writing to the other by notice as aforesaid.

13.   ASSIGNABILITY:

<PAGE>

      This Agreement (a) may not be assigned by WINCHESTER and (b) shall be
      binding on MEDASORB's successors and assigns.

14.   WAIVER:

      The failure of any party at any time or times to require the performance
      of any provisions of this Agreement will in no manner affect the right at
      a later time to enforce it. No waiver by any party of any condition or of
      the breach of any term contained in this Agreement, whether by conduct or
      otherwise, in any one or more instances, will be deemed to be or construed
      as a further or continuing waiver of the breach of any other term of this
      Agreement.

15.   SEVERABILITY:

      The invalidity or unenforceability of any provision of this Agreement will
      not affect any other provision, and the remainder of the Agreement will be
      construed as if the invalid and unenforceable provision were omitted.

16.   POWERS AND AUTHORITY:

      Each party represents and warrants that it has the right, power and
      authority to enter into this Agreement, and to fully perform its
      respective obligations hereunder.

17.   ENTIRE AGREEMENT:

      This Agreement sets forth the entire agreement and understanding of the
      parties in respect of the subject matter and supercedes any and all prior
      agreements, arrangements, understandings and representations relating to
      the subject matter.

18.   GOVERNING LAW:

      This Agreement will be governed by and construed in accordance with the
      laws of the State of New York applicable to contracts made and to be
      performed entirely within that State.

19.   MISCELLANEOUS:

      19.1  Binding Effect

            This Agreement will be binding on and inure to the benefit of the
            parties hereto and their respective heirs, legal representatives,
            successors and assigns.

      19.2  Headings

            Paragraph headings are inserted for convenience or reference only
            and do not form a party of this Agreement, and no construction or
            inference will be derived therefrom.

<PAGE>

      19.3  Counterparts

            This Agreement may be executed simultaneously in two or more
            counterparts, each of which will be deemed an original, but all of
            which together will constitute one and the same instrument.

      19.4  Amendment; Waiver, Etc.

            This Agreement may be amended, modified, superceded or canceled, and
            any of its terms may be waived, only by a written instrument
            executed by each party or, in the case of a waiver, by the party or
            parties waiving compliance.

      IN WITNESS WHEREOF, the parties have caused this Agreement to be duly
executed on the day and year first above written.

                                    MEDASORB TECHNOLOGIES, LLC

                                    By:_____________________________
                                          Al Kraus, President and CEO

                                    By:_____________________________
                                          James Winchester, M.D.

<PAGE>

                                    Exhibit A

      Chief Nephrologist at Beth Israel Medical Center

      Professor at Beth Israel Medical Center, includes teaching, medical care
      and other activities in conjunction with the Renal Research Institute

      Editorial Work with respect to Advances in Renal Replacement Therapy

      Adjunct Professor at Down State Medical Center

      Invited Lecturer

      Expect Witness Assignments

      Medical Association Executive PositionsUnassociated Document

    2006
      LONG-TERM INCENTIVE PLAN

     

    OF
      

     

    GILDER
      ENTERPRISES, INC.

     

    I. Purpose

     

    The
      purpose of the Gilder Enterprises, Inc. 2006 Long-Term Incentive Plan (the
      “Plan”) is to attract and retain and provide incentives to employees, officers,
      directors and consultants of the Corporation and its Subsidiaries, and to
      thereby increase overall stockholders’ value. The Plan generally provides for
      the granting of stock, stock options, stock appreciation rights, restricted
      shares or any combination of the foregoing to the eligible
      participants.

     

    II. Definitions

     

    (a) “Award”
      includes, without limitation, stock options (including incentive stock options
      within the meaning of Section 422(b) of the Code), stock appreciation rights,
      dividend equivalent rights, stock awards, restricted share awards, or other
      awards that are valued in whole or in part by reference to, or are otherwise
      based on, the Common Stock (“other Common Stock-based Awards”), all on a stand
      alone, combination or tandem basis, as described in or granted under this
      Plan.

     

    (b) “Award
      Agreement” means a written agreement setting forth the terms and conditions of
      each Award made under this Plan.

     

    (c) “Board”
      means the Board of Directors of the Corporation.

     

    (d) “Code”
      means the Internal Revenue Code of 1986, as amended from time to
      time.

     

    (e) “Committee”
      means the Compensation Committee of the Board or such other committee of the
      Board as may be designated by the Board from time to time to administer this
      Plan or if no such committee is designated, the Board. 

     

    (f) “Common
      Stock” means the common stock of the Corporation, par value $.001 per share, or
      any other securities of the Corporation into which such common stock is
      reclassified or reconstituted.

     

    (g) “Corporation”
      means Gilder Enterprises, Inc., a Nevada corporation.

     

    (h) “Employee”
      means an employee of the Corporation or a Subsidiary.

     

    (i) “Exchange
      Act” means the Securities Exchange Act of 1934, as amended, and the rules and
      regulations thereunder.

     

    (j) “Fair
      Market Value” means (i) if the Common Stock is listed on an established stock
      exchange or exchanges or the NASDAQ National Market, the closing price per
      share
      on the last trading day immediately preceding such date on the principal
      exchange on which it is traded or as reported by NASDAQ; or (b) if the Common
      Stock is not then listed on an exchange or the NASDAQ National Market, but
      is
      quoted on the NASDAQ Capital Market, the NASD OTC bulletin board or the National
      Quotation Bureau pink sheets, the average of the closing bid and asked prices
      per share for the Common Stock as quoted by the NASD or the National Quotation
      Bureau, as the case may be, on the last trading day immediately preceding such
      date; or (c) if the Common Stock is not then listed on an exchange or the NASDAQ
      National Market, or quoted by NASD or the National Quotation Bureau, an amount
      determined in good faith by resolution of the Committee (whose determination
      shall be conclusive), based on the best information available to
      it.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    (k) “Participant”
      means an Employee, officer, director or consultant who has been granted an
      Award
      under the Plan.

     

    (l) “Plan
      Year” means a twelve-month period beginning with January 1 of each
      year.

     

    (l) “Subsidiary”
      means any corporation or other entity, whether domestic or foreign, in which
      the
      Corporation has or obtains, directly or indirectly, a proprietary interest
      of
      more than 50% by reason of stock ownership or otherwise.

     

    III. Eligibility

     

    Any
      Employee, officer, director or consultant of the Corporation or a Subsidiary
      selected by the Committee is eligible to receive an Award.

     

    IV. Plan
      Administration

     

    (a) Except
      as
      otherwise determined by the Board, the Plan shall be administered by the
      Committee. The Board, or the Committee to the extent determined by the Board,
      shall periodically make determinations with respect to the participation of
      Employees, officers, directors and consultants in the Plan and, except as
      otherwise required by law or this Plan, the grant terms of Awards, including
      vesting schedules, price, restriction or option periods, dividend rights,
      post-retirement and termination rights, payment alternatives such as cash,
      stock, contingent awards or other means of payment consistent with the purposes
      of this Plan, and such other terms and conditions as the Board or the Committee
      deems appropriate which shall be contained in an Award Agreement with respect
      to
      a Participant.

     

    (b) The
      Committee shall have authority to interpret and construe the provisions of
      the
      Plan and any Award Agreement and make determinations pursuant to any Plan
      provision or Award Agreement which shall be final and binding on all persons.
      No
      member of the Committee shall be liable for any action or determination made
      in
      good faith, and the members shall be entitled to indemnification and
      reimbursement in the manner provided in the Corporation’s Certificate of
      Incorporation, as it may be amended from time to time.

     

    (c) The
      Committee shall have the authority at any time to provide for the conditions
      and
      circumstances under which Awards shall be forfeited. The Committee shall have
      the authority to accelerate the vesting of any Award and the times at which
      any
      Award becomes exercisable.

     

    V. Capital
      Stock Subject to the Provisions of this Plan

     

    (a) The
      capital stock subject to the provisions of this Plan shall be shares of
      authorized but unissued Common Stock and shares of Common Stock held as treasury
      stock. Subject to adjustment in accordance with the provisions of Section X,
      and
      Sections V(b) and (c) below, the total number of shares of Common Stock
      available for grants of Awards shall not exceed 2,500,000.

     

    (b) The
      grant
      of a restricted share Award shall be deemed to be equal to the maximum number
      of
      shares which may be issued under the Award. Awards payable only in cash will
      not
      reduce the number of shares available for Awards granted under the
      Plan.

     

    (c) There
      shall be carried forward and be available for Awards under the Plan, in addition
      to shares available for grant under paragraph (a) of this Section V, all of
      the
      following: (i) any unused portion of the limit set forth in paragraph (a) of
      this Section V; (ii) shares represented by Awards which are cancelled,
      forfeited, surrendered, terminated, paid in cash or expire unexercised; and
      (iii) the excess amount of variable Awards which become fixed at less than
      their
      maximum limitations.

     

    VI. Awards
      Under This Plan

     

    As
      the
      Committee may determine, the following types of Awards and other Common
      Stock-based Awards may be granted under this Plan on a stand alone, combination
      or tandem basis:

     

     

    (a) Stock
      Option.
      A right
      to buy a specified number of shares of Common Stock at a fixed exercise price
      during a specified time, all as the Committee may determine.

     

    (b) Incentive
      Stock Option.
      An
      Award in the form of a stock option which shall comply with the requirements
      of
      Section 422 of the Code or any successor section as it may be amended from
      time
      to time. Subject to adjustment in accordance with the provisions of Section
      X,
      the aggregate number of shares which may be subject to incentive stock option
      Awards under this Plan shall not exceed 2,500,000, subject to Section V above.
      To the extent that Section 422 of the Code requires certain provisions to be
      set
      forth in a written plan, said provisions are incorporated herein by this
      reference.

     

    (c) Stock
      Appreciation Right.
      A
      right, which may or may not be contained in the grant of a stock option or
      incentive stock option, to receive in cash (or its equivalent value in Common
      Stock) the excess of the Fair Market Value of a share of Common Stock on the
      date the right is surrendered over the option exercise price or other price
      specified in the Award Agreement.

     

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

    (d) Restricted
      Shares.
      The
      issuance of Common Stock to a Participant subject to forfeiture until such
      restrictions, terms and conditions as the Committee may determine are
      fulfilled.

     

    (e) Dividend
      or Equivalent.
      A right
      to receive dividends or their equivalent in value in Common Stock, cash or
      in a
      combination of both with respect to any new or previously existing
      Award.

     

    (f) Stock
      Award.
      The
      issuance of Common Stock, which may be on a contingent basis, to a
      Participant.

     

    (g) Other
      Stock-Based Awards.
      Other
      Common Stock-based Awards which are related to or serve a similar function
      to
      those Awards set forth in this Section VI.

     

    VII. Award
      Agreements

     

    Each
      Award under the Plan shall be evidenced by an Award Agreement that shall set
      forth the terms and conditions of the Award and shall be executed by the
      Corporation and the Participant.

     

    VIII. Other
      Terms and Conditions

     

    (a) Assignability.
      Unless
      provided to the contrary in any Award, no Award shall be assignable or
      transferable except by will or by the laws of descent and distribution and
      during the lifetime of a Participant, the Award shall be exercisable only by
      such Participant.

     

    (b) Termination
      of Employment or Other Relationship.
      The
      Committee shall determine the disposition of the grant of each Award in the
      event of the retirement, disability, death or other termination of a
      Participant’s employment or other relationship with the Corporation or a
      Subsidiary.

     

    (c) Rights
      as a Stockholder.
      A
      Participant shall have no rights as a stockholder with respect to shares covered
      by an Award until the date the Participant is the holder of record. Except
      as
      provided in Section X, no adjustment will be made for dividends or other rights
      for which the record date is prior to such date.

     

    (d) No
      Obligation to Exercise.
      The
      grant of an Award shall impose no obligation upon the Participant to exercise
      the Award.

     

    (e) Payments
      by Participants.
      The
      Committee may determine that Awards for which a payment is due from a
      Participant may be payable: (i) in U.S. dollars by personal check, bank draft
      or
      money order payable to the order of the Corporation, by money transfers or
      direct account debits; (ii) through the delivery or deemed delivery based on
      attestation to the ownership of shares of Common Stock with a Fair Market Value
      equal to the total payment due from the Participant; (iii) pursuant to a
      broker-assisted “cashless exercise” program if established by the Corporation;
      (iv) by a combination of the methods described in (i) through (iii) above;
      or
      (v) by such other methods as the Committee may deem appropriate.

     

    (f) Withholding.
      Except
      as otherwise provided by the Committee, (i) the deduction of withholding and
      any
      other taxes required by law will be made from all amounts paid in cash and
      (ii)
      in the case of payments of Awards in shares of Common Stock, the Participant
      shall be required to pay the amount of any taxes required to be withheld prior
      to receipt of such stock, or alternatively, a number of shares the Fair Market
      Value of which equals the amount required to be withheld may be deducted from
      the payment.

     

    (g) Maximum
      Awards.
      The
      maximum number of shares of Common Stock that may be issued to any single
      Participant pursuant to Awards under this Plan in any single Plan Year is
      2,500,000.

     

    IX. Termination,
      Modification and Amendments

     

    (a) The
      Plan
      may from time to time be terminated, modified or amended by the affirmative
      vote
      of the holders of a majority of the outstanding shares of the capital stock
      of
      the Corporation present or represented and entitled to vote at a duly held
      stockholders meeting.

     

    (b) Notwithstanding
      the provisions of Section IX(a) above, the Board may at any time terminate
      the
      Plan or from time to time make such modifications or amendments of the Plan
      as
      it may deem advisable; provided, however, that the Board shall not make any
      material amendments to the Plan without the approval of at least the affirmative
      vote of the holders of a majority of the outstanding shares of the capital
      stock
      of the Corporation present or represented and entitled to vote at a duly held
      stockholders meeting.

     

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

    (c) No
      termination, modification or amendment of the Plan may adversely affect the
      rights conferred by an Award without the consent of the recipient
      thereof.

     

    X. Recapitalization

     

    The
      aggregate number of shares of Common Stock as to which Awards may be granted
      to
      Participants, the number of shares thereof covered by each outstanding Award
      and
      the price per share thereof in each such Award, shall all be proportionately
      adjusted for any increase or decrease in the number of issued shares of Common
      Stock resulting from a subdivision or consolidation of shares or other capital
      adjustment, or the payment of a stock dividend or other increase or decrease
      in
      such shares, effected without receipt of consideration by the Corporation,
      or
      other change in corporate or capital structure; provided, however, that any
      fractional shares resulting from any such adjustment shall be eliminated. The
      Committee may also make the foregoing changes and any other changes, including
      changes in the classes of securities available, to the extent it is deemed
      necessary or desirable to preserve the intended benefits of the Plan for the
      Corporation and the Participants in the event of any other reorganization,
      recapitalization, merger, consolidation, spin-off, extraordinary dividend or
      other distribution or similar transaction.

     

    XI. No
      Right to Employment

     

    No
      person
      shall have any claim or right to be granted an Award, and the grant of an Award
      shall not be construed as giving a Participant the right to be retained in
      the
      employ of, or in any other relationship with, the Corporation or a Subsidiary.
      Further, the Corporation and each Subsidiary expressly reserve the right at
      any
      time to dismiss a Participant free from any liability, or any claim under the
      Plan, except as provided herein or in any Award Agreement issued
      hereunder.

     

    XII. Governing
      Law

     

    To
      the
      extent that federal laws do not otherwise control, the Plan shall be construed
      in accordance with and governed by the laws of the State of Nevada.

     

    XIII. Savings
      Clause

     

    This
      Plan
      is intended to comply in all aspects with applicable laws and regulations.
      In
      case any one or more of the provisions of this Plan shall be held invalid,
      illegal or unenforceable in any respect under applicable law and regulation,
      the
      validity, legality and enforceability of the remaining provisions shall not
      in
      any way be affected or impaired thereby and the invalid, illegal or
      unenforceable provision shall be deemed null and void; however, to the extent
      permissible by law, any provision which could be deemed null and void shall
      first be construed, interpreted or revised retroactively to permit this Plan
      to
      be construed in compliance with all applicable laws so as to foster the intent
      of this Plan.

     

    XIV. Effective
      Date and Term

     

    The
      effective date of this Plan is June __, 2006. The Plan shall terminate on June
      __, 2016. No awards shall be granted after the termination of the
      Plan.

     

    
      
         

      

      
        4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00106-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00106-of-00352.parquet"}]]